Study of Suramin in Subjects With Furosemide-Resistant AKI

Inclusion Criteria: * At least 18 years of age at the time of signing the informed consent * KDIGO Stage I AKI and a serum Cr increase ≥ 0.3 mg/dL within 48 hr or 1.5 to 1.9-times baseline (pre-FST) Cr levels within 48 hr (± 6 hr) prior to randomization OR KDIGO Stage II AKI and serum Cr increase 2.0 to 2.9-times baseline (pre-FST) Cr levels within 48 hr (± 6 hr) prior to randomization * Fails to achieve a 200 mL increase in urine output within 2 hr following a 1.0 mg/kg bolus of furosemide (i.e., positive FST) * If female of childbearing potential, must have a negative pregnancy test at Screening Is capable of providing informed consent as described in in this protocol. Exclusion Criteria: * Receiving hemodialysis or peritoneal dialysis * Prior renal transplant (other organ transplants are not excluded) * Known baseline (pre-FST) estimated glomerular filtration rate (eGFR) ≤ 20 mL/min * Evidence of hydronephrosis or obstructive uropathy confirmed by renal ultrasound (for subjects without a documented ultrasound, the * Investigator will determine if a renal ultrasound is indicated, consistent with the standard of care (SOC) * Hepatic encephalopathy, Child class C cirrhosis, and/or clinical suspicion of hepatorenal syndrome * International normalized ratio (INR) ≤ 3.0, unless on stable long-term warfarin therapy within 2 weeks prior to randomization * Known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection * Known coronavirus (COVID-19) infection * White blood cell count (WBC) \< 2,000/μL and/or platelet count \< 30,000/μL at the time of Screening * A sequential organ failure assessment (SOFA) score \> 10 during Screening * Subjects requiring 3 or more vasopressor agents of any combination to maintain a mean arterial pressure \> 65 mm Hg * Unwilling to participate in follow-up phone surveys up to 180 days post-treatment * Are enrolled in another interventional research study or have participated in another interventional study within 14 days of Screening.